NCT03446001已完成3 期
Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 598
- 试验地点
- 98
- 主要终点
- Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control)
研究概览
简要总结
The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo. In addition, an open-label, delayed-start phase is included to demonstrate a disease-modifying effect of TRx0237.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- — 至 90 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Alzheimer's Disease (AD), encompassing probable AD and mild cognitive impairment due to AD (MCI-AD) based on the 2011 National Institute on Aging and Alzheimer's Association (NIA/AA) criteria
- •Documented PET scan that is positive for amyloid
- •Mini-Mental State Examination (MMSE) score of 16-27 (inclusive), subject to stratification requirements
- •Global Clinical Dementia Rating (CDR) of 0.5 to 2 (if 0.5, including a score of >0 in one of the functional domains: Community Affairs, Home and Hobbies, or Personal Care)
- •Age <90 years
- •Females must be surgically sterile, have undergone bilateral tubal occlusion / ligation, be post-menopausal, or use adequate contraception
- •Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with local and national law is/are able to read, understand, and provide written informed consent in the designated language of the study site
- •Has one or more identified adult study partner who either lives with the subject or has sufficient contact to provide assessment of changes in subject behavior and function over time and information on safety and tolerability; is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language(s) at the study site; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug
- •Must not be taking an acetylcholinesterase inhibitor and/or memantine for at least 60 days at the time of the Baseline assessments
- •Able to comply with the study procedures in the view of the Investigator
排除标准
- •Significant central nervous system disorder other than probable AD or MCI-AD
- •Significant intracranial focal or vascular pathology seen on brain MRI scan that would lead to a diagnosis other than probable AD or MCI-AD
- •Clinical evidence or history of cerebrovascular accident; transient ischemic attack; significant head injury, for example, associated loss of consciousness, skull fracture or persisting cognitive impairment; other unexplained or recurrent loss of consciousness for ≥15 minutes
- •Epilepsy (a single prior seizure >6 months prior to Screening is considered acceptable)
- •Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria met for major depressive disorder; schizophrenia; other psychotic disorders, bipolar disorder; substance (including alcohol) related disorders
- •Metal implants in the head, pacemaker, cochlear implants, or any other non-removable items that are contraindications to MRI
- •Resides in hospital or moderate to high dependency continuous care facility
- •Any physical disability that would prevent completion of study procedures or assessments
- •History of swallowing difficulties
- •Pregnant or breastfeeding
- •Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- •History of significant hematological abnormality or current acute or chronic clinically significant abnormality
- •Abnormal serum chemistry laboratory value at Screening deemed to be clinically significant by the Investigator
- •Clinically significant cardiovascular disease or abnormal electrocardiogram assessments
- •Pre-existing or current signs or symptoms of respiratory failure
- •Concurrent acute or chronic clinically significant immunologic, hepatobiliary, or endocrine disease and/or other unstable or major disease other than probable AD or MCI-AD
- •Diagnosis of cancer (excluding basal cell carcinoma, squamous cell carcinoma, or prostate carcinoma in situ [Stage 1]) within the past 2 years or a previous (>2 years) diagnosis of cancer that has required any form of intervention or treatment within the past 2 years
- •Prior intolerance or hypersensitivity to methylthioninium (MT)-containing drug or methemoglobinemia induced by MT-containing drug, similar organic dyes, or any of the excipients
- •Treatment currently or within 90 days before Baseline with Souvenaid®, clozapine, carbamazepine, primidone, valproate, or drugs for which there is a warning or precaution in the labeling about methemoglobinemia at approved doses
- •Current or prior participation in any clinical trial of TRx0237; a clinical trial of a product for cognition prior to Baseline in which the last dose was received within 90 days prior to Baseline unless confirmed to have been randomized to placebo; or a clinical trial of any other investigational drug, biologic, device, or medical food in which the last dose was received within 28 days prior to Baseline
研究组 & 干预措施
TRx0237 16 mg/day
Experimental
干预措施: TRx0237 16 mg/day (Drug)
Control
Placebo Comparator
干预措施: Control (Drug)
TRx0237 8 mg/day
Experimental
干预措施: TRx0237 8 mg/day (Drug)
结局指标
主要结局
Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control)
时间窗: 52 weeks
This primary outcome measure was assessed in the TRx0237 16 mg/day group compared to the control group. The scores on this scale range from 0 to 70, with higher numbers indicating a worse outcome (greater impairment).
Change From Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) (16 mg/Day vs Control)
时间窗: 52 weeks
This primary outcome measure was assessed in the TRx0237 16 mg/day group compared to the control group. The scores on this scale range from 0 to 78, with higher numbers indicating a better outcome (lower impairment).
Number of Study Participants With Serious and Non-serious Adverse Events (16 mg/Day vs Control)
时间窗: 52 weeks
This primary outcome measure was assessed in the TRx0237 16 mg/day group compared to the placebo group. All laboratory test or vital sign parameter abnormalities deemed clinically significant by the Investigator are to be reported as adverse events.
次要结局
- Change in Annualized Rate of Whole Brain Atrophy (16 mg/Day vs Control)(52 weeks)
- Change in Standardized Uptake Value Ratio (SUVR) Based on Temporal Lobe 18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG-PET) (16 mg/Day vs Control)(52 weeks)
- Change in Annualized Rate of Temporoparietal Lobe Atrophy (16 mg/Day vs Control)(52 weeks)
- Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (8 mg/Day vs Control)(52 weeks)
- Change From Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) (8 mg/Day vs Control)(52 weeks)
- Change in Standardized Uptake Value Ratio (SUVR) Based on Temporal Lobe 18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG-PET) (8 mg/Day vs Control)(52 weeks)
- Change in Annualized Rate of Temporoparietal Lobe Atrophy (8 mg/Day vs Control)(52 weeks)
- Change From Open-Label Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)(104 weeks)
- Number of Study Participants With Serious and Non-serious Adverse Events (8 mg/Day vs Control)(52 weeks)
- Number of Study Participants With Serious and Non-serious Adverse Events (Open-label)(104 weeks)
研究者
研究点 (98)
Loading locations...
相似试验
终止
2 期
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01626391TauRx Therapeutics Ltd9
已完成
3 期
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)Behavioral Variant Frontotemporal Dementia (bvFTD)NCT01626378TauRx Therapeutics Ltd220
已完成
3 期
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01689246TauRx Therapeutics Ltd891
已完成
3 期
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's DiseaseAlzheimer's DiseaseNCT01689233TauRx Therapeutics Ltd800
已完成
2 期
A Study of Crofelemer to Treat Diarrhea Irritable Bowel SyndromeColonic DiseasesDiarrheaGastrointestinal DiseaseIrritable Bowel SyndromeNCT00101725Bausch Health Americas, Inc.245